Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay5087 in Advanced Solid Tumors
NCT07624864Phase 1Not yet recruiting
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Jul 2026
- Primary completion
- Apr 2028
01
Overview
Phase 1, open-label, single-arm trial of Hemay5087 in solid tumor, sponsored by Hemay Pharmaceutical Technology. Primary endpoints: Number of participants with adverse events at 3 weeks, Incidence of dose-limiting toxicity at 3 weeks and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Hemay5087
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07624864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624864.